ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer
Gianopulos, J. E. et al. (2026) ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. Nature Communications , (doi: 10.1038/s41467-026-73380-x…
Read the full articleYou might also wanna read
ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer
ZNF274 limits pancreatic cancer plasticity by maintaining chromatin and suppressing genes. Loss of ZNF274 shifts from classical to invasive
Study reveals how opposing oncogenic and tumor-suppressive forces converge to drive benign-to-malignant transition in pancreatic cancer
Opposing oncogenic and tumor-suppressive forces establish a progenitor-like state that builds a self-reinforcing niche to drive benign-to-ma
Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes
Clonal hematopoiesis (CH) is the age-related expansion of mutated hematopoietic stem cells without hematologic abnormalities. In patients wi
Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase–initiated genetically engineered mouse model
CIC::DUX4 sarcoma (CDS) is a lethal cancer driven by a fusion between the tumor suppressor capicua (CIC) and the pioneer transcription facto
SLC15A3-mediated dipeptide metabolism confers antimetabolite resistance in lymphoma via mTORC1 activation
Antimetabolites, chemotherapy targeting nucleotide biosynthesis, are among the oldest and most widely used cancer treatments, yet resistance
Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma
Cells use plasticity programs to change lineages, which aids in tissue regeneration and remodeling but also allows aberrant cells to become
Comments
Sign in to join the conversation.
No comments yet. Be the first.